Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Mitochondrial DNA Levels in Blood and Tissue Samples from Breast Cancer Patients of Different Stages

  • Xia, Peng (Department of Oncology Surgery, First Affiliated Hospital, Xi'an Jiaotong University) ;
  • Wang, Hui-Juan (School of Life Sciences, Northwest University) ;
  • Geng, Ting-Ting (School of Life Sciences, Northwest University) ;
  • Xun, Xiao-Jie (School of Life Sciences, Northwest University) ;
  • Zhou, Wen-Jing (School of Life Sciences, Northwest University) ;
  • Jin, Tian-Bo (School of Life Sciences, Northwest University) ;
  • Chen, Chao (School of Life Sciences, Northwest University)
  • Published : 2014.02.01
Download PDF
⟨ Previous Next ⟩

Abstract

Aims: Alterations in mitochondrial DNA (mtDNA) have been implicated in carcinogenesis and tumor progression. We here evaluated the diagnostic and prognostic potential of mtDNA as a biomarker for breast cancer. Methods: Using multiplex real-time polymerase chain reaction, nuclear DNA (nDNA) and mtDNA levels in serum, buffy coat, tumor, and tumor-adjacent tissue samples from 50 breast cancer patients were determined and assessed for associations with clinicopathological features. To evaluate mtDNA as a biomarker for distinguishing between the four sample types, we created receiver operating characteristic (ROC) curves. Results: The mtDNA levels in buffy coat were significantly lower than in other sample types. Relative to tumor-adjacent tissue, reduced levels of mtDNA were identified in buffy coat and tumor tissue but not in serum. According to ROC curve analysis, mtDNA levels could be used to distinguish between buffy coat and tumor-adjacent tissue samples with good sensitivity (77%) and specificity (83%). Moreover, mtDNA levels in serum and tumor tissue were positively associated with cancer TMN stage. Conclusions: The mtDNA levels in blood samples may represent a promising, non-invasive biomarker in breast cancer patients. Additional, large-scale validation studies are required to establish the potential use of mtDNA levels in the early diagnosis and monitoring of breast cancer.

Keywords

References

  1. Barrientos A, Casademont J, Cardellach F, et al (1997). Reduced steady-state levels of mitochondrial RNA and increased mitochondrial DNA amount in human brain with aging. Brain Res Mol Brain Res, 52, 284-9. https://doi.org/10.1016/S0169-328X(97)00278-7
  2. Bewick V, Cheek L, Ball J (2004). Statistics review 10: further nonparametric methods. Crit Care, 8, 196-9. https://doi.org/10.1186/cc2857
  3. Copeland WC, Wachsman JT, Johnson FM, Penta JS (2002). Mitochondrial DNA alterations in cancer. Cancer Invest, 20, 557-69. https://doi.org/10.1081/CNV-120002155
  4. Dai JG, Zhang ZY, Liu QX, Min JX (2013). Mitochondrial genome microsatellite instability and copy number alteration in lung carcinomas. Asian Pac J Cancer Prev, 14, 2393-9. https://doi.org/10.7314/APJCP.2013.14.4.2393
  5. Dani MA, Dani SU, Lima SP, et al (2004). Less DeltamtDNA4977 than normal in various types of tumors suggests that cancer cells are essentially free of this mutation. Genet Mol Res, 3, 395-409.
  6. Fan AX, Radpour R, Haghighi MM, et al (2009). Mitochondrial DNA content in paired normal and cancerous breast tissue samples from patients with breast cancer. J Cancer Res Clin Oncol, 135, 983-9. https://doi.org/10.1007/s00432-008-0533-9
  7. Fliss MS, Usadel H, Caballero OL, et al (2000). Facile detection of mitochondrial DNA mutations in tumors and bodily fluids. Science, 287, 2017-9. https://doi.org/10.1126/science.287.5460.2017
  8. Gonzalez-Masia JA, Garcia-Olmo D, Garcia-Olmo DC (2013). Circulating nucleic acids in plasma and serum (CNAPS): applications in oncology. Onco Targets Ther, 6, 819-32.
  9. Hibi K, Nakayama H, Yamazaki T, et al (2001). Detection of mitochondrial DNA alterations in primary tumors and corresponding serum of colorectal cancer patients. Int J Cancer, 94, 429-31. https://doi.org/10.1002/ijc.1480
  10. Jeronimo C, Nomoto S, Caballero OL, et al (2001). Mitochondrial mutations in early stage prostate cancer and bodily fluids. Oncogene, 20, 5195-8. https://doi.org/10.1038/sj.onc.1204646
  11. Jiang WW, Masayesva B, Zahurak M, et al (2005). Increased mitochondrial DNA content in saliva associated with head and neck cancer. Clin Cancer Res, 11, 2486-91. https://doi.org/10.1158/1078-0432.CCR-04-2147
  12. Jiang WW, Rosenbaum E, Mambo E, et al (2006). Decreased mitochondrial DNA content in posttreatment salivary rinses from head and neck cancer patients. Clin Cancer Res, 12, 1564-9. https://doi.org/10.1158/1078-0432.CCR-05-1471
  13. Jones JB, Song JJ, Hempen PM, et al (2001). Detection of mitochondrial DNA mutations in pancreatic cancer offers a "mass"-ive advantage over detection of nuclear DNA mutations. Cancer Res, 61, 1299-304.
  14. Kohler C, Radpour R, Barekati Z, et al (2009). Levels of plasma circulating cell free nuclear and mitochondrial DNA as potential biomarkers for breast tumors. Mol Cancer, 8, 105. https://doi.org/10.1186/1476-4598-8-105
  15. Lee HC, Li SH, Lin JC, et al (2004). Somatic mutations in the D-loop and decrease in the copy number of mitochondrial DNA in human hepatocellular carcinoma. Mutat Res, 547, 71-8. https://doi.org/10.1016/j.mrfmmm.2003.12.011
  16. Mambo E, Chatterjee A, Xing M, et al (2005). Tumor-specific changes in mtDNA content in human cancer. Int J Cancer, 116, 920-4. https://doi.org/10.1002/ijc.21110
  17. Mehra N, Penning M, Maas J, et al (2007). Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer. Clin Cancer Res, 13, 421-6. https://doi.org/10.1158/1078-0432.CCR-06-1087
  18. Mizumachi T, Muskhelishvili L, Naito A, et al (2008). Increased distributional variance of mitochondrial DNA content associated with prostate cancer cells as compared with normal prostate cells. Prostate, 68, 408-17. https://doi.org/10.1002/pros.20697
  19. Morten KJ, Ashley N, Wijburg F, et al (2007). Liver mtDNA content increases during development: a comparison of methods and the importance of age- and tissue-specific controls for the diagnosis of mtDNA depletion. Mitochondrion, 7, 386-95. https://doi.org/10.1016/j.mito.2007.09.001
  20. Nomoto S, Yamashita K, Koshikawa K, Nakao A, Sidransky D (2002). Mitochondrial D-loop mutations as clonal markers in multicentric hepatocellular carcinoma and plasma. Clin Cancer Res, 8, 481-7.
  21. Okochi O, Hibi K, Uemura T, et al (2002). Detection of mitochondrial DNA alterations in the serum of hepatocellular carcinoma patients. Clin Cancer Res, 8, 2875-8.
  22. Radpour R, Fan AX, Kohler C, Holzgreve W, Zhong XY (2009). Current understanding of mitochondrial DNA in breast cancer. Breast J, 15, 505-9. https://doi.org/10.1111/j.1524-4741.2009.00767.x
  23. Selvanayagam P, Rajaraman S (1996). Detection of mitochondrial genome depletion by a novel cDNA in renal cell carcinoma. Lab Invest, 74, 592-9.
  24. Shen J, Platek M, Mahasneh A, Ambrosone CB, Zhao H (2010). Mitochondrial copy number and risk of breast cancer: a pilot study. Mitochondrion, 10, 62-8. https://doi.org/10.1016/j.mito.2009.09.004
  25. Thyagarajan B, Wang R, Nelson H, et al (2013). Mitochondrial DNA copy number is associated with breast cancer risk. PLoS One, 8, e65968. https://doi.org/10.1371/journal.pone.0065968
  26. Tseng LM, Yin PH, Chi CW, et al (2006). Mitochondrial DNA mutations and mitochondrial DNA depletion in breast cancer. Genes Chromosomes Cancer, 45, 629-38. https://doi.org/10.1002/gcc.20326
  27. Wang K, Yuan Y, Cho JH, et al (2012). Comparing the MicroRNA spectrum between serum and plasma. PLoS One, 7, e41561. https://doi.org/10.1371/journal.pone.0041561
  28. Wang Y, Liu VW, Xue WC, Cheung AN, Ngan HY (2006). Association of decreased mitochondrial DNA content with ovarian cancer progression. Br J Cancer, 95, 1087-91. https://doi.org/10.1038/sj.bjc.6603377
  29. Wang Y, Liu VW, Xue WC, et al (2005). The increase of mitochondrial DNA content in endometrial adenocarcinoma cells: a quantitative study using laser-captured microdissected tissues. Gynecol Oncol, 98, 104-10. https://doi.org/10.1016/j.ygyno.2005.04.015
  30. Weigel MT, Dowsett M (2010). Current and emerging biomarkers in breast cancer: prognosis and prediction. Endocr Relat Cancer, 17, R245-62. https://doi.org/10.1677/ERC-10-0136
  31. Wu CW, Yin PH, Hung WY, et al (2005). Mitochondrial DNA mutations and mitochondrial DNA depletion in gastric cancer. Genes Chromosomes Cancer, 44, 19-28. https://doi.org/10.1002/gcc.20213
  32. Xia P, An HX, Dang CX, et al (2009a). Decreased mitochondrial DNA content in blood samples of patients with stage I breast cancer. BMC Cancer, 9, 454. https://doi.org/10.1186/1471-2407-9-454
  33. Xia P, Radpour R, Zachariah R, et al (2009b). Simultaneous quantitative assessment of circulating cell-free mitochondrial and nuclear DNA by multiplex real-time PCR. Genet Mol Biol, 32, 20-4. https://doi.org/10.1590/S1415-47572009000100003
  34. Xing J, Chen M, Wood CG, et al (2008). Mitochondrial DNA content: its genetic heritability and association with renal cell carcinoma. J Natl Cancer Inst, 100, 1104-12. https://doi.org/10.1093/jnci/djn213
  35. Yin PH, Lee HC, Chau GY, et al (2004). Alteration of the copy number and deletion of mitochondrial DNA in human hepatocellular carcinoma. Br J Cancer, 90, 2390- 6.
  36. Yu M (2011). Generation, function and diagnostic value of mitochondrial DNA copy number alterations in human cancers. Life Sci, 89, 65-71. https://doi.org/10.1016/j.lfs.2011.05.010
  37. Yu M, Zhou Y, Shi Y, et al (2007). Reduced mitochondrial DNA copy number is correlated with tumor progression and prognosis in Chinese breast cancer patients. IUBMB Life, 59, 450-7. https://doi.org/10.1080/15216540701509955
  38. Zhu W, Qin W, Sauter ER (2004). Large-scale mitochondrial DNA deletion mutations and nuclear genome instability in human breast cancer. Cancer Detect Prev, 28, 119-26. https://doi.org/10.1016/j.cdp.2003.11.008

Cited by

  1. Elevated Serum Levels of Heat Shock Protein 70 Are Associated with Breast Cancer vol.236, pp.2, 2015, https://doi.org/10.1620/tjem.236.97
  2. gene polymorphisms are associated with breast cancer risk in a Chinese Han population vol.19, pp.12, 2017, https://doi.org/10.1002/jgm.2996
  3. MMP8 and MMP9 gene polymorphisms were associated with breast cancer risk in a Chinese Han population vol.8, pp.1, 2018, https://doi.org/10.1038/s41598-018-31664-3